Evidence map›Paper›PMID 29641836›Full record

ArticleJAMA cardiology2018

Association of Cardiomyopathy With MYBPC3 D389V and MYBPC3Δ25bpIntronic Deletion in South Asian Descendants.

Shiv Kumar Viswanathan, Megan J Puckelwartz, Ashish Mehta, Chrishan J A Ramachandra, Aravindakshan Jagadeesan, Regina Fritsche-Danielson, Ratan V Bhat, Philip Wong, Sangeetha Kandoi, Jennifer A Schwanekamp and 16 more

Open access · bronzeAbstract read
In one paragraph

Article in JAMA cardiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Review
  3. Cells · 2024
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. South Asian-SpecificFrontiers in cardiovascular medicine · 2021
    Article
  15. Review
  16. Review
  17. Reevaluation of the South AsianCirculation. Genomic and precision medicine · 2020
    Article
  18. South Asian-SpecificCirculation. Genomic and precision medicine · 2020
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 11 institutions in 5 countries.

Shiv Kumar ViswanathanHeart, Lung and Vascular Institute, Department of Internal Medicine, University of Cincinnati, Cincinnati, Ohio.
Megan J PuckelwartzCenter for Genetic Medicine, Northwestern University, Chicago, Illinois.
Ashish MehtaNational Heart Research Institute Singapore.
Chrishan J A RamachandraNational Heart Research Institute Singapore.
Aravindakshan JagadeesanDepartment of Cell and Molecular Physiology, Loyola University Chicago, Maywood, Illinois.
Regina Fritsche-DanielsonCardiovascular and Metabolic Disease Innovative Medicines and Early Development Unit, AstraZeneca Research and Development, Gothenburg, Sweden.
Ratan V BhatCardiovascular and Metabolic Disease Innovative Medicines and Early Development Unit, AstraZeneca Research and Development, Gothenburg, Sweden.
Philip WongNational Heart Research Institute Singapore.
Sangeetha KandoiHeart, Lung and Vascular Institute, Department of Internal Medicine, University of Cincinnati, Cincinnati, Ohio.
Jennifer A SchwanekampHeart, Lung and Vascular Institute, Department of Internal Medicine, University of Cincinnati, Cincinnati, Ohio.
Gina KuffelDepartment of Public Health Sciences, Loyola University Chicago, Maywood, Illinois.
Lorenzo L PesceComputation Institute, The University of Chicago, Chicago, Illinois.
Michael J ZillioxDepartment of Public Health Sciences, Loyola University Chicago, Maywood, Illinois.
U Nalla B DuraiDivison of Hematology and Oncology, University of Illinois at Chicago.
Rama Shanker VermaDepartment of Biotechnology, Indian Institute of Technology Madras, Chennai, Tamilnadu, India.
Robert E MolokieDivison of Hematology and Oncology, University of Illinois at Chicago.
Domodhar P SureshSt Elizabeth Physicians Heart and Vascular, Florence, Kentucky.
Philip R KhouryHeart Institute, Cincinnati Children's Hospital, Cincinnati, Ohio.
Annie ThomasMarcella Niehoff School of Nursing, Loyola University Chicago, Maywood, Illinois.
Thriveni SanagalaDepartment of Cardiology and Echocardiography and Cardiographics, Loyola University Chicago, Maywood, Illinois.
Hak Chiaw TangDepartment of Cardiology, National Heart Centre Singapore, Singapore.
Richard C BeckerHeart, Lung and Vascular Institute, Department of Internal Medicine, University of Cincinnati, Cincinnati, Ohio.
Ralph KnöllCardiovascular and Metabolic Disease Innovative Medicines and Early Development Unit, AstraZeneca Research and Development, Gothenburg, Sweden.
Winston ShimNational Heart Research Institute Singapore.
Elizabeth M McNallyCenter for Genetic Medicine, Northwestern University, Chicago, Illinois.
Sakthivel SadayappanHeart, Lung and Vascular Institute, Department of Internal Medicine, University of Cincinnati, Cincinnati, Ohio.
Loyola University Chicago · USUniversity of Cincinnati · USNational Heart Centre Singapore · SGAstraZeneca (Sweden) · SENorthwestern University · USUniversity of Illinois Chicago · USCincinnati Children's Hospital Medical Center · USDuke-NUS Medical School · SGIndian Institute of Technology Madras · INSt. Elizabeth Healthcare · USUniversity of Chicago · US

Funding

Cardiomyopathy Genomes ProjectR01HL128075 · NHLBI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI MCNALLY, ELIZABETH M, NOBREGA, MARCELO A. · 2015 to 2023
$5.3M
Fast myosin binding protein-C and cardiac contractility in heart failureR01HL105826 · NHLBI · UNIVERSITY OF CINCINNATI · PI SADAYAPPAN, SAKTHIVEL · 2011 to 2025
$4.5M
Understanding Cardiovascular Disease MechanismsT32HL125204 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI Evangelia G Kranias, Jeffery D Molkentin · 2015 to 2026
$3.4M
Molecular mechanism of hypertrophic cardiomyopathy in populations of South Asian descendantsR01HL130356 · NHLBI · UNIVERSITY OF CINCINNATI · PI SADAYAPPAN, SAKTHIVEL · 2016 to 2019
$1.6M
Proteomic approaches to validate novel cardiac biomarkers for myocardial infarctiK02HL114749 · NHLBI · UNIVERSITY OF CINCINNATI · PI SADAYAPPAN, SAKTHIVEL · 2012 to 2016
$498k
NHLBI NIH HHS K02 HL114749NHLBI NIH HHS R01 HL105826NHLBI NIH HHS R01 HL128075NHLBI NIH HHS R01 HL130356NHLBI NIH HHS T32 HL125204
6 · The paper itself

Abstract

Importance: The genetic variant MYBPC3Δ25bp occurs in 4% of South Asian descendants, with an estimated 100 million carriers worldwide. MYBPC3 Δ25bp has been linked to cardiomyopathy and heart failure. However, the high prevalence of MYBPC3Δ25bp suggests that other stressors act in concert with MYBPC3Δ25bp. Objective: To determine whether there are additional genetic factors that contribute to the cardiomyopathic expression of MYBPC3Δ25bp. Design, Setting, andParticipants: South Asian individuals living in the United States were screened for MYBPC3Δ25bp, and a subgroup was clinically evaluated using electrocardiograms and echocardiograms at Loyola University, Chicago, Illinois, between January 2015 and July 2016. Main Outcomes and Measures: Next-generation sequencing of 174 cardiovascular disease genes was applied to identify additional modifying gene mutations and correlate genotype-phenotype parameters. Cardiomyocytes derived from human-induced pluripotent stem cells were established and examined to assess the role of MYBPC3Δ25bp. Results: In this genotype-phenotype study, individuals of South Asian descent living in the United States from both sexes (36.23% female) with a mean population age of 48.92 years (range, 18-84 years) were recruited. Genetic screening of 2401 US South Asian individuals found an MYBPC3Δ25bpcarrier frequency of 6%. A higher frequency of missense TTN variation was found in MYBPC3Δ25bp carriers compared with noncarriers, identifying distinct genetic backgrounds within the MYBPC3Δ25bp carrier group. Strikingly, 9.6% of MYBPC3Δ25bp carriers also had a novel MYBPC3 variant, D389V. Family studies documented D389V was in tandem on the same allele as MYBPC3Δ25bp, and D389V was only seen in the presence of MYBPC3Δ25bp. In contrast to MYBPC3Δ25bp, MYBPC3Δ25bp/D389V was associated with hyperdynamic left ventricular performance (mean [SEM] left ventricular ejection fraction, 66.7 [0.7%]; left ventricular fractional shortening, 36.6 [0.6%]; P < .03) and stem cell-derived cardiomyocytes exhibited cellular hypertrophy with abnormal Ca2+ transients. Conclusions and Relevance: MYBPC3Δ25bp/D389V is associated with hyperdynamic features, which are an early finding in hypertrophic cardiomyopathy and thought to reflect an unfavorable energetic state. These findings support that a subset of MYBPC3Δ25bp carriers, those with D389V, account for the increased risk attributed to MYBPC3Δ25bp.

Indexed as

AdolescentAdultAgedAged, 80 and overAsianCardiomyopathy, HypertrophicCarrier ProteinsFemaleGenotypeHumansMaleMiddle AgedMutationMyosin Binding Protein CPhenotypeStroke VolumeCarrier ProteinsMyosin Binding Protein C

Identifiers

PMID29641836
PMCPMC6054452
OpenAlexW2796702939

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.